FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283329> ?p ?o ?g. }

• W4379283329 endingPage "3142" @default.
• W4379283329 startingPage "3142" @default.
• W4379283329 abstract "3142 Background: Most cancer patients with chronic hepatitis C virus (HCV) infection are excluded from cancer clinical trials (CCTs). The use of direct-acting antivirals (DAAs) to eradicate HCV and allow access to CCTs in HCV-infected cancer patients has not been studied. We aimed to evaluate the efficacy and safety of DAA treatment to increase access to CCTs in patients with chronic HCV infection and hematologic malignancies (HM). Methods: HCV-infected patients with HM seen at MD Anderson Cancer Center between 01/01/2016 and 01/31/2023 were enrolled in a prospective observational study. Those initially excluded from CCTs and then treated with DAAs to allow that cancer treatment were further analyzed (cases). HCV-infected cancer patients treated with DAAs but never enrolled in CCTs were used as controls. The 1:1 matching between cases and controls was based on the cancer type and stage, history of > 3 types of chemotherapy, and presence of cirrhosis. The primary outcomes were the efficacy and safety of DAAs. The secondary outcomes were overall survival (OS) and progression-free survival (PFS). Results: Twenty-four patients with HM initially excluded from CCTs because of HCV were enrolled. Twelve of them (50%) received DAAs to have access to CCTs and they were matched to 12 controls. Most of the cases were men (10; 83%), white (6; 50%), non-cirrhotic (10; 83%), and with HCV genotype 1 (9; 75%). Most patients in the control group were men (7; 58%), white (9; 75%), non-cirrhotic (8; 67%), and with HCV genotype 1 (9; 75%). Among the entire study group, adverse events occurred in 6 of the 24 patients (25%), and all were grade 1-2. No HCV-associated liver failure or death occurred. The overall sustained virologic response (microbiologic cure) after completion of antiviral therapy was 92%. Median OS was 74 months in the cases vs 52 months in the controls, median PFS was 30 months in the cases vs 33 months in the controls. When compared to controls in multivariate analysis, cases had significantly better OS (hazard ratio = 0.23, 95% CI = 0.06 to 0.85, p = 0.027). No significant differences were noted in PFS (p=0.13). Death due to progressive HM occurred in all 12 controls (100%) but only in 4 cases (33%) (p=0.001). Conclusions: DAA treatment increases access to CCTs and improves OS in patients with chronic HCV infection and HM. HCV infection should not be considered a contraindication to investigational cancer treatment. The use of DAAs to facilitate access CCTs could become one of the most common indications for DAAs in HCV-infected cancer patients." @default.
• W4379283329 created "2023-06-05" @default.
• W4379283329 creator A5001237986 @default.
• W4379283329 creator A5005436649 @default.
• W4379283329 creator A5007730121 @default.
• W4379283329 creator A5008785159 @default.
• W4379283329 creator A5033699674 @default.
• W4379283329 creator A5035605515 @default.
• W4379283329 creator A5055182697 @default.
• W4379283329 creator A5060313982 @default.
• W4379283329 creator A5088307376 @default.
• W4379283329 date "2023-06-01" @default.
• W4379283329 modified "2023-09-23" @default.
• W4379283329 title "Treatment of chronic hepatitis C virus infection to increase access to cancer clinical trials in patients with hematologic malignancies: A prospective observational study." @default.
• W4379283329 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.3142" @default.
• W4379283329 hasPublicationYear "2023" @default.
• W4379283329 type Work @default.
• W4379283329 citedByCount "0" @default.
• W4379283329 crossrefType "journal-article" @default.
• W4379283329 hasAuthorship W4379283329A5001237986 @default.
• W4379283329 hasAuthorship W4379283329A5005436649 @default.
• W4379283329 hasAuthorship W4379283329A5007730121 @default.
• W4379283329 hasAuthorship W4379283329A5008785159 @default.
• W4379283329 hasAuthorship W4379283329A5033699674 @default.
• W4379283329 hasAuthorship W4379283329A5035605515 @default.
• W4379283329 hasAuthorship W4379283329A5055182697 @default.
• W4379283329 hasAuthorship W4379283329A5060313982 @default.
• W4379283329 hasAuthorship W4379283329A5088307376 @default.
• W4379283329 hasConcept C121608353 @default.
• W4379283329 hasConcept C126322002 @default.
• W4379283329 hasConcept C143998085 @default.
• W4379283329 hasConcept C203014093 @default.
• W4379283329 hasConcept C23131810 @default.
• W4379283329 hasConcept C2522874641 @default.
• W4379283329 hasConcept C2776231280 @default.
• W4379283329 hasConcept C2776408679 @default.
• W4379283329 hasConcept C2776455275 @default.
• W4379283329 hasConcept C2777214474 @default.
• W4379283329 hasConcept C71924100 @default.
• W4379283329 hasConcept C90924648 @default.
• W4379283329 hasConceptScore W4379283329C121608353 @default.
• W4379283329 hasConceptScore W4379283329C126322002 @default.
• W4379283329 hasConceptScore W4379283329C143998085 @default.
• W4379283329 hasConceptScore W4379283329C203014093 @default.
• W4379283329 hasConceptScore W4379283329C23131810 @default.
• W4379283329 hasConceptScore W4379283329C2522874641 @default.
• W4379283329 hasConceptScore W4379283329C2776231280 @default.
• W4379283329 hasConceptScore W4379283329C2776408679 @default.
• W4379283329 hasConceptScore W4379283329C2776455275 @default.
• W4379283329 hasConceptScore W4379283329C2777214474 @default.
• W4379283329 hasConceptScore W4379283329C71924100 @default.
• W4379283329 hasConceptScore W4379283329C90924648 @default.
• W4379283329 hasIssue "16_suppl" @default.
• W4379283329 hasLocation W43792833291 @default.
• W4379283329 hasOpenAccess W4379283329 @default.
• W4379283329 hasPrimaryLocation W43792833291 @default.
• W4379283329 hasRelatedWork W1565805196 @default.
• W4379283329 hasRelatedWork W1982541345 @default.
• W4379283329 hasRelatedWork W2008626862 @default.
• W4379283329 hasRelatedWork W2053370422 @default.
• W4379283329 hasRelatedWork W2146236851 @default.
• W4379283329 hasRelatedWork W2151663174 @default.
• W4379283329 hasRelatedWork W2166316093 @default.
• W4379283329 hasRelatedWork W2399201228 @default.
• W4379283329 hasRelatedWork W2517087858 @default.
• W4379283329 hasRelatedWork W2954945993 @default.
• W4379283329 hasVolume "41" @default.
• W4379283329 isParatext "false" @default.
• W4379283329 isRetracted "false" @default.
• W4379283329 workType "article" @default.